MyFinsight
Home
Blog
About
Sales and maturities
of marketable...
$9,786K
(-73.94%↓ Y/Y)
Proceeds from shares
issued under espp
$22K
(15.79%↑ Y/Y)
Net cash provided by
investing activities
$9,786K
(-9.83%↓ Y/Y)
Net cash provided by
financing activities
$22K
(-98.91%↓ Y/Y)
Net increase
(decrease) in cash and cash...
$93K
(100.41%↑ Y/Y)
Canceled cashflow
$9,715K
Asset impairment
$5,077K
Stock-based compensation
$304K
(-84.42%↓ Y/Y)
Depreciation and
amortization
$272K
(-78.87%↓ Y/Y)
Prepaid expenses and
other assets
-$195K
(-111.36%↓ Y/Y)
Noncash operating lease
expense
$161K
(-44.10%↓ Y/Y)
Accrued liabilities and
other liabilities
-$13K
(99.68%↑ Y/Y)
Net cash used in
operating activities
-$9,715K
(72.79%↑ Y/Y)
Canceled cashflow
$6,022K
Net loss
-$14,892K
(60.59%↑ Y/Y)
Accounts payable
-$492K
(82.48%↑ Y/Y)
Lease liabilities
-$276K
(43.44%↑ Y/Y)
Amortization of premiums and
discounts on marketable...
$41K
(-89.38%↓ Y/Y)
Other long-term
liabilities
-$36K
(45.45%↑ Y/Y)
Back
Back
Cash Flow
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)
source: myfinsight.com